Literature DB >> 23341329

Using primary site as a predictor of survival in mantle cell lymphoma.

Alexander J Ambinder1, Pareen J Shenoy, Loretta J Nastoupil, Christopher R Flowers.   

Abstract

BACKGROUND: Mantle cell lymphoma (MCL) is a rare B cell lymphoma that varies in clinical behavior with some patients experiencing aggressive disease with short survival, whereas others have indolent behavior. We examined the association between primary disease site and survival in MCL patients to identify subgroups with distinct characteristics.
METHODS: We analyzed the United States Surveillance, Epidemiology and End Results Program database for MCL cases reported from 2000 through 2009. Kaplan-Meier curves and Cox proportional hazard models were used to estimate the effect of primary site on survival.
RESULTS: Among 4477 cases included in our study, 19.6% of patients presented with an extranodal primary site. The most common extranodal primary sites were of the gastrointestinal (GI) tract (7.8%), the head and neck (6.2%), and the hematologic/reticuloendothelial systems (3.6%). Asians/Pacific Islanders were more likely than whites or blacks to have GI tract or head and neck disease (P < .0001 and P = .002, respectively). Advanced disease and B symptoms were less common in those with primary disease of the GI tract or head and neck than in those with primary disease of the lymph nodes (both P < .0001). In a multivariate Cox regression model, patients with primary disease of the GI tract and head and neck had superior survival compared to those with primary disease of the lymph nodes; hazard ratios 0.75 (95% CI = 0.62-0.90) and 0.68 (95% CI = 0.55-0.85), respectively.
CONCLUSIONS: Primary site of disease may be an important prognostic factor for patients with MCL. Further studies elucidating a biological basis for these differences are needed.
Copyright © 2013 American Cancer Society.

Entities:  

Mesh:

Year:  2013        PMID: 23341329     DOI: 10.1002/cncr.27898

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Do mantle cell lymphomas have an 'Achilles heel'?

Authors:  Nakhle Saba; Adrian Wiestner
Journal:  Curr Opin Hematol       Date:  2014-07       Impact factor: 3.284

2.  Gastrointestinal Mantle Cell Lymphoma with Varied Findings.

Authors:  Atsushi Goto; Jun Nishikawa; Shunsuke Ito; Eizaburou Hideura; Tomohiro Shirasawa; Koichi Hamabe; Shinichi Hashimoto; Takeshi Okamoto; Isao Sakaida
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Hematolymphoid Tumours.

Authors:  Noah A Brown; Kojo S J Elenitoba-Johnson
Journal:  Head Neck Pathol       Date:  2017-02-28

4.  Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.

Authors:  Oscar Calzada; Jeffrey M Switchenko; Joseph J Maly; Kristie A Blum; Natalie Grover; Stephanie Mathews; Steven I Park; Max Gordon; Alexey Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Christopher R Flowers; Jonathon B Cohen
Journal:  Leuk Lymphoma       Date:  2018-06-18

Review 5.  Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature.

Authors:  Maria Georgaki; Vasileios Ionas Theofilou; Efstathios Pettas; Evangelia Piperi; Eleana Stoufi; Panayiotis Panayiotidis; Nikolaos G Nikitakis
Journal:  Head Neck Pathol       Date:  2021-10-30

Review 6.  Next-generation prognostic assessment for diffuse large B-cell lymphoma.

Authors:  Ashley D Staton; Jean L Koff; Qiushi Chen; Turgay Ayer; Christopher R Flowers
Journal:  Future Oncol       Date:  2015-08-20       Impact factor: 3.404

7.  Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Karin E Smedby; Joshua N Sampson; Jennifer J Turner; Susan L Slager; Marc Maynadié; Eve Roman; Thomas M Habermann; Christopher R Flowers; Sonja I Berndt; Paige M Bracci; Henrik Hjalgrim; Dennis D Weisenburger; Lindsay M Morton
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

8.  Management of Primary Gastrointestinal Non-Hodgkin Lymphomas: a Population-Based Survival Analysis.

Authors:  Evan Michael Shannon; Ian T MacQueen; Jeffrey M Miller; Melinda Maggard-Gibbons
Journal:  J Gastrointest Surg       Date:  2016-03-18       Impact factor: 3.452

9.  Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.

Authors:  Muhammad Furqan; Yamei Chen; Akintunde Akinleye; Judy Sarungbam; Alan Gass; Karen Seiter; Delong Liu
Journal:  Front Med       Date:  2014-03-14       Impact factor: 4.592

Review 10.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.